See more : Parkin Company P.J.S.C. (PARKIN.AE) Income Statement Analysis – Financial Results
Complete financial analysis of Landec Corporation (LNDC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Landec Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Synektik Spólka Akcyjna (SNT.WA) Income Statement Analysis – Financial Results
- SaltX Technology Holding AB (publ) (SALT-B.ST) Income Statement Analysis – Financial Results
- United States Cellular Corporat (UZE) Income Statement Analysis – Financial Results
- ExcelFin Acquisition Corp. (XFIN) Income Statement Analysis – Financial Results
- Australian Agricultural Company Limited (AAC.AX) Income Statement Analysis – Financial Results
Landec Corporation (LNDC)
About Landec Corporation
Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. Landec Corporation was incorporated in 1986 and is headquartered in Santa Maria, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 185.79M | 544.16M | 590.37M | 557.56M | 524.23M | 532.26M | 541.10M | 539.26M | 476.81M | 441.71M | 317.55M | 276.73M | 238.22M | 235.94M | 238.53M | 210.50M | 231.95M | 205.23M | 192.09M | 0.00 | 190.88M | 209.55M | 35.40M | 33.50M | 9.50M | 2.50M |
| Cost of Revenue | 135.42M | 462.69M | 515.38M | 476.56M | 445.89M | 449.07M | 470.14M | 473.85M | 414.25M | 378.95M | 265.41M | 230.03M | 204.46M | 201.66M | 200.30M | 178.11M | 191.91M | 173.26M | 162.30M | 0.00 | 163.30M | 170.12M | 19.30M | 18.20M | 5.10M | 500.00K |
| Gross Profit | 50.37M | 81.47M | 74.99M | 81.00M | 78.34M | 83.19M | 70.96M | 65.41M | 62.56M | 62.76M | 52.14M | 46.70M | 33.77M | 34.28M | 38.23M | 32.39M | 40.04M | 31.97M | 29.79M | 0.00 | 27.59M | 39.43M | 16.10M | 15.30M | 4.40M | 2.00M |
| Gross Profit Ratio | 27.11% | 14.97% | 12.70% | 14.53% | 14.94% | 15.63% | 13.11% | 12.13% | 13.12% | 14.21% | 16.42% | 16.87% | 14.17% | 14.53% | 16.03% | 15.39% | 17.26% | 15.58% | 15.51% | 0.00% | 14.45% | 18.82% | 45.48% | 45.67% | 46.32% | 80.00% |
| Research & Development | 7.84M | 10.22M | 11.10M | 11.47M | 12.80M | 9.47M | 7.23M | 6.99M | 7.20M | 9.29M | 9.63M | 9.28M | 4.36M | 3.67M | 3.25M | 3.07M | 3.04M | 2.54M | 3.73M | 0.00 | 3.27M | 4.70M | 5.80M | 5.70M | 7.60M | 3.80M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 46.13M | 65.36M | 72.19M | 64.06M | 51.95M | 55.63M | 49.52M | 39.96M | 35.17M | 32.53M | 26.52M | 24.61M | 17.70M | 18.02M | 19.80M | 21.62M | 27.98M | 23.41M | 22.00M | 0.00 | 26.97M | 28.88M | 11.20M | 10.80M | 4.70M | 3.30M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.93M | 1.42M | 4.78M | 0.00 | 0.00 | 0.00 | -22.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.07M | 2.20M | 2.10M | 1.10M | 500.00K |
| Operating Expenses | 53.97M | 75.59M | 83.29M | 75.53M | 64.75M | 65.10M | 56.74M | 46.95M | 42.37M | 37.89M | 37.56M | 38.66M | 22.06M | 21.68M | 23.05M | 2.02M | 31.02M | 25.96M | 25.74M | 0.00 | 30.24M | 39.64M | 19.20M | 18.60M | 13.40M | 7.60M |
| Cost & Expenses | 189.38M | 538.27M | 598.67M | 552.08M | 510.64M | 514.17M | 526.89M | 520.80M | 456.62M | 416.84M | 302.98M | 268.70M | 226.52M | 223.34M | 223.35M | 180.13M | 222.93M | 199.21M | 188.04M | 0.00 | 193.53M | 209.76M | 38.50M | 36.80M | 18.50M | 8.10M |
| Interest Income | 81.00K | 48.00K | 103.00K | 145.00K | 211.00K | 16.00K | 71.00K | 315.00K | 260.00K | 179.00K | 180.00K | 430.00K | 834.00K | 1.31M | 2.22M | 1.95M | 633.00K | 214.00K | 247.00K | 0.00 | 617.00K | 617.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 17.36M | 15.34M | 9.60M | 5.23M | 1.95M | 1.83M | 1.99M | 1.83M | 1.65M | 2.01M | 929.00K | 820.00K | 88.00K | 8.00K | -22.00K | -251.00K | -452.00K | -414.00K | -1.55M | 0.00 | -2.79M | -2.79M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 17.88M | 19.87M | 18.84M | 15.23M | 12.41M | 10.68M | 9.40M | 7.09M | 7.11M | 7.30M | 5.62M | 5.31M | 3.36M | 3.14M | 3.20M | 3.26M | 3.20M | 3.47M | 3.71M | 0.00 | 5.43M | 6.07M | 2.20M | 2.10M | 1.10M | 500.00K |
| EBITDA | -46.28M | -13.50M | -22.87M | 22.39M | 29.83M | 27.43M | -7.66M | 18.46M | 20.19M | 24.87M | 14.58M | 14.23M | 11.70M | 16.49M | 15.18M | 34.91M | 9.02M | 6.02M | 4.06M | 0.00 | -13.36M | 2.03M | -500.00K | -600.00K | -7.50M | -3.70M |
| EBITDA Ratio | -36.62% | -0.97% | -3.87% | 4.02% | 5.69% | 5.15% | -1.42% | 5.60% | 8.07% | 9.36% | 8.32% | 5.14% | 4.91% | 6.99% | 8.43% | 16.58% | 5.11% | 4.32% | 3.44% | 0.00% | -7.00% | 0.97% | -1.41% | -1.79% | -78.95% | -148.00% |
| Operating Income | -85.91M | -25.12M | -41.70M | 7.16M | 11.85M | 16.28M | -17.06M | 16.95M | 18.80M | 23.04M | 13.83M | 7.64M | 12.45M | 13.35M | 15.18M | 30.37M | 9.02M | 6.02M | 2.90M | 0.00 | -18.79M | -4.04M | -2.70M | -2.70M | -8.60M | -4.20M |
| Operating Income Ratio | -46.24% | -4.62% | -7.06% | 1.28% | 2.26% | 3.06% | -3.15% | 3.14% | 3.94% | 5.22% | 4.35% | 2.76% | 5.23% | 5.66% | 6.36% | 14.43% | 3.89% | 2.93% | 1.51% | 0.00% | -9.84% | -1.93% | -7.63% | -8.06% | -90.53% | -168.00% |
| Total Other Income/Expenses | -5.84M | -15.34M | -9.60M | -3.52M | 4.55M | -1.26M | -1.79M | 4.52M | 11.13M | 7.40M | 6.46M | 410.00K | -3.73M | -8.00K | 1.72M | 1.28M | -396.00K | -619.00K | 0.00 | 0.00 | 13.95M | 521.00K | 0.00 | 0.00 | 1.70M | 1.50M |
| Income Before Tax | -52.12M | -40.47M | -51.31M | 3.64M | 16.40M | 15.01M | -18.85M | 21.47M | 29.93M | 32.26M | 20.28M | 8.44M | 8.73M | 13.34M | 16.90M | 31.65M | 8.63M | 5.40M | 2.93M | 0.00 | -4.84M | -2.13M | -2.70M | -2.70M | -6.90M | -2.70M |
| Income Before Tax Ratio | -28.05% | -7.44% | -8.69% | 0.65% | 3.13% | 2.82% | -3.48% | 3.98% | 6.28% | 7.30% | 6.39% | 3.05% | 3.66% | 5.65% | 7.08% | 15.03% | 3.72% | 2.63% | 1.52% | 0.00% | -2.53% | -1.01% | -7.63% | -8.06% | -72.63% | -108.00% |
| Income Tax Expense | -5.84M | -7.80M | -13.12M | 1.52M | -9.36M | 4.34M | -7.40M | 7.75M | 10.58M | 9.45M | 7.19M | 4.18M | 4.26M | 5.61M | 3.35M | 2.46M | -24.00K | -4.00K | 29.00K | 0.00 | 3.04M | -42.00K | 100.00K | 200.00K | 1.70M | 1.50M |
| Net Income | -46.28M | -32.67M | -38.19M | 2.12M | 25.76M | 10.68M | -11.45M | 13.73M | 19.34M | 22.81M | 13.10M | 4.26M | 4.47M | 7.73M | 13.54M | 29.19M | 8.65M | 5.40M | 2.90M | 0.00 | -18.79M | -2.08M | -2.80M | -2.90M | -8.60M | -4.20M |
| Net Income Ratio | -24.91% | -6.00% | -6.47% | 0.38% | 4.91% | 2.01% | -2.12% | 2.55% | 4.06% | 5.16% | 4.12% | 1.54% | 1.87% | 3.28% | 5.68% | 13.87% | 3.73% | 2.63% | 1.51% | 0.00% | -9.84% | -0.99% | -7.91% | -8.66% | -90.53% | -168.00% |
| EPS | -1.57 | -1.11 | -1.31 | 0.07 | 0.92 | 0.39 | -0.42 | 0.51 | 0.72 | 0.86 | 0.51 | 0.16 | 0.17 | 0.30 | 0.52 | 1.16 | 0.35 | 0.23 | 0.14 | 0.00 | -1.15 | -0.13 | -0.21 | -0.23 | -0.77 | -0.55 |
| EPS Diluted | -1.57 | -1.11 | -1.31 | 0.07 | 0.92 | 0.39 | -0.42 | 0.50 | 0.71 | 0.86 | 0.50 | 0.16 | 0.17 | 0.29 | 0.50 | 1.10 | 0.34 | 0.22 | 0.12 | 0.00 | -1.15 | -0.13 | -0.21 | -0.22 | -0.77 | -0.55 |
| Weighted Avg Shares Out | 29.47M | 29.33M | 29.22M | 29.10M | 27.92M | 27.50M | 27.15M | 26.99M | 26.82M | 26.40M | 25.64M | 26.41M | 26.36M | 26.18M | 26.07M | 25.26M | 24.55M | 23.71M | 21.40M | 21.11M | 16.37M | 15.80M | 13.27M | 12.77M | 11.14M | 7.70M |
| Weighted Avg Shares Out (Dil) | 29.47M | 29.33M | 29.22M | 29.10M | 27.92M | 27.65M | 27.15M | 27.34M | 27.12M | 26.63M | 26.13M | 26.63M | 26.63M | 26.75M | 26.94M | 26.56M | 25.66M | 24.61M | 23.56M | 22.86M | 16.37M | 15.80M | 13.27M | 13.33M | 11.14M | 7.70M |
Landec Corporation (LNDC) CEO Albert Bolles on Q1 2022 Results - Earnings Call Transcript
Landec Corporation (LNDC) CEO Albert Bolles on Q1 2022 Results - Earnings Call Transcript
Landec (LNDC) Reports Q1 Loss, Tops Revenue Estimates
Landec (LNDC) delivered earnings and revenue surprises of -109.09% and 0.42%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?
Landec Corporation Reports First Quarter Fiscal Year 2022 Results
SANTA MARIA, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. and Curation Foods, Inc., reported results for the fiscal 2022 first quarter ended August 29,...
Will Landec (LNDC) Report Negative Earnings Next Week? What You Should Know
Landec (LNDC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Landec Still In Play As An Activist Investment
Activist activity could serve as a potential catalyst event, helping realize intrinsic value.
Landec Corporation (LNDC) CEO Albert Bolles on Q4 2021 Results - Earnings Call Transcript
Landec Corporation (LNDC) CEO Albert Bolles on Q4 2021 Results - Earnings Call Transcript
Landec (LNDC) Q4 Earnings and Revenues Surpass Estimates
Landec (LNDC) delivered earnings and revenue surprises of 333.33% and 12.41%, respectively, for the quarter ended May 2021. Do the numbers hold clues to what lies ahead for the stock?
Landec: Q4 Earnings Insights
Shares of Landec (NASDAQ:LNDC) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 40.00% over the past year to $0.07, which beat the estimate of ($0.01).
Landec Corporation Sets Fourth Quarter 2021 Earnings Conference Call for July 28, 2021 at 2 p.m. PT
SANTA MARIA, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (Nasdaq: LNDC), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. and Curation Foods, Inc., will hold a conference call on Wednesday, July 28, 2021...
Landec Sells Investment in Windset Holdings
Early sale to affiliates of founding and controlling investors for $45.1 million
Source: https://incomestatements.info
Category: Stock Reports